When: 8:00 am to 2:00 pm, Saturday, February 7th, 2015
Where: Knobbe Martens (12790 El Camino Real, San Diego, CA 92130)
Fee: $20 online by January 25; $10 for students and post-docs. $40 onsite. Registration fee includes parking, program brochure, breakfast, coffee, and lunch.
Registration Link: https://www.123signup.com/event?id=ysmzj
Forum Title: “Breakthrough Technologies Accelerating diagnosis and Filling the Therapeutic Gap for Rare and Genetic Diseases”
Forum Summary: According to a 2013 Rare Disease Impact Report conducted by Shire, the economic impact of diagnosing and management of rare disease is substantial. One of the key findings the report revealed is that it takes, on average, more than seven years for a rare disease patient in the US to receive an accurate diagnosis. There are 6,000 rare disease recognized by NIH and yet only approximately 200 of these illnesses have effective pharmacologic treatment coverage. There is a gap of medicines and therapies that can address certain unmet medical needs of rare disease patients that has major growth potential for pharma and device companies in the market for orphan disease.
SABPA Medical Device and Diagnostic Forum will bring together stakeholders of in research, academia, regulatory and investment to foster partnerships that will boost the development of medical device, drug, and biological products for rare disease patients. Ultimately improving the diagnosis, treatment and care of patients and their families.
Speakers and Panelists
Keynote Speaker: Research and Drug Development for Rare Diseases: NIH Initiatives and Resources
Rashmi Gopal-Srivastava, Ph.D., Director, Extramural Research Program, Office of Rare Diseases Research (ORDR), NCATS, NIH
Solving the Unsolvable: the Genomics Revolution at Our Fingertips, Ryan Taft, Ph.D., Director Scientific Research, Illumina, Inc.
Key FDA Challenges in Bringing Orphan Drugs to the Market in the United States, Michael Swift, J.D., Senior Director, Compliance & Regulatory, Legal, Illumina, Inc.
Home-based Non-invasive Brain Monitoring for Individuals with Rare Neurological Conditions
Philip Low, Ph.D., Founder, Chairman & CEO, Neurovigil Inc.
Venture Philanthropy: A Novel Approach for Funding Rare Disease Research, John Wetherell, Ph.D., Partner, Pillsbury Winthrop Shaw Pittman
Panel Discussion: New approaches to overcome obstacles and drive discovery and innovation for faster patient impact
Moderator: Christina Waters, Ph.D., CEO & Founder, Rare Science
Christian Braemer, CEO & CO-Founder, Benefunder
Dr. Hudson Freeze, Director, Human Genetics Program, Sanford Children’s Health Research Center
Dr. Philip Low, Founder, Chairman & CEO Neurovigil Inc.
John Walmsley, VP Product Development, Starfish Medical
Kim Goodsell, Patient Advocate